The Importance of CD44 As a Stem Cell Biomarker and Therapeutic Target in Cancer

Overview

Journal Stem Cells Int

Publisher Wiley

Specialty Cell Biology

Date 2016 May 21

PMID 27200096

Citations 128

Authors

Ranjeeta Thapa

George D Wilson

Affiliations

Soon will be listed here.

Abstract

CD44 is a cell surface HA-binding glycoprotein that is overexpressed to some extent by almost all tumors of epithelial origin and plays an important role in tumor initiation and metastasis. CD44 is a compelling marker for cancer stem cells of many solid malignancies. In addition, interaction of HA and CD44 promotes EGFR-mediated pathways, consequently leading to tumor cell growth, tumor cell migration, and chemotherapy resistance in solid cancers. Accumulating evidence indicates that major HA-CD44 signaling pathways involve a specific variant of CD44 isoforms; however, the particular variant almost certainly depends on the type of tumor cell and the stage of the cancer progression. Research to date suggests use of monoclonal antibodies against different CD44 variant isoforms and targeted inhibition of HA/CD44-mediated signaling combined with conventional radio/chemotherapy may be the most favorable therapeutic strategy for future treatments of advanced stage malignancies. Thus, this paper briefly focuses on the association of the major CD44 variant isoforms in cancer progression, the role of HA-CD44 interaction in oncogenic pathways, and strategies to target CD44-overexpressed tumor cells.

Citing Articles

Tumor-initiating and metastasis-initiating cells of clear-cell renal cell carcinoma.

Pham D, Hsu T J Biomed Sci. 2025; 32(1):17.

PMID: 39920694 PMC: 11806631. DOI: 10.1186/s12929-024-01111-9.

Strategies to Overcome Intrinsic and Acquired Resistance to Chemoradiotherapy in Head and Neck Cancer.

de Bakker T, Maes A, Dragan T, Martinive P, Penninckx S, Van Gestel D Cells. 2025; 14(1.

PMID: 39791719 PMC: 11719474. DOI: 10.3390/cells14010018.

Global profiling of alternative splicing in non-small cell lung cancer reveals novel histological and population differences.

Zeeshan S, Dalal B, Arauz R, Zingone A, Harris C, Khiabanian H Oncogene. 2025; .

PMID: 39789165 DOI: 10.1038/s41388-024-03267-y.

E-cigarettes increase the risk of adenoma formation in murine colorectal cancer model.

Sayed I, Chakraborty A, Inouye K, Dugan L, Tocci S, Advani I Arch Toxicol. 2025; 99(3):1223-1236.

PMID: 39786590 DOI: 10.1007/s00204-024-03932-x.

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD).

Angelicola S, Giunchi F, Ruzzi F, Frascino M, Pitzalis M, Scalambra L J Transl Med. 2025; 23(1):2.

PMID: 39748404 PMC: 11697469. DOI: 10.1186/s12967-024-06023-8.

References

Toole B . Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004; 4(7):528-39. DOI: 10.1038/nrc1391. View

Toole B . Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities. Clin Cancer Res. 2009; 15(24):7462-7468. PMC: 2796593. DOI: 10.1158/1078-0432.CCR-09-0479. View

Toole B, Slomiany M . Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat. 2008; 11(3):110-21. PMC: 2584579. DOI: 10.1016/j.drup.2008.04.002. View

Louderbough J, Schroeder J . Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res. 2011; 9(12):1573-86. DOI: 10.1158/1541-7786.MCR-11-0156. View

Afify A, Tate S, Durbin-Johnson B, Rocke D, Konia T . Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Int J Biol Markers. 2011; 26(1):50-7. DOI: 10.5301/jbm.2011.6291. View

El-Dakdouki M, Zhu D, El-Boubbou K, Kamat M, Chen J, Li W . Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells. Biomacromolecules. 2012; 13(4):1144-51. PMC: 5475368. DOI: 10.1021/bm300046h. View

Underhill C, Toole B . Binding of hyaluronate to the surface of cultured cells. J Cell Biol. 1979; 82(2):475-84. PMC: 2110457. DOI: 10.1083/jcb.82.2.475. View

Reategui E, de Mayolo A, Das P, Astor F, Singal R, Hamilton K . Characterization of CD44v3-containing isoforms in head and neck cancer. Cancer Biol Ther. 2006; 5(9):1163-8. DOI: 10.4161/cbt.5.9.3065. View

Hirata K, Suzuki H, Imaeda H, Matsuzaki J, Tsugawa H, Nagano O . CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer. 2013; 109(2):379-86. PMC: 3721391. DOI: 10.1038/bjc.2013.314. View

10.

Leung E, Fiscus R, Tung J, Tin V, Cheng L, Sihoe A . Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 2010; 5(11):e14062. PMC: 2988826. DOI: 10.1371/journal.pone.0014062. View

11.

Gottesman M, Ling V . The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006; 580(4):998-1009. DOI: 10.1016/j.febslet.2005.12.060. View

12.

Luo Y, Ziebell M, Prestwich G . A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules. 2001; 1(2):208-18. DOI: 10.1021/bm000283n. View

13.

Deerinck T . The application of fluorescent quantum dots to confocal, multiphoton, and electron microscopic imaging. Toxicol Pathol. 2008; 36(1):112-6. PMC: 2771444. DOI: 10.1177/0192623307310950. View

14.

Wielenga V, van der Neut R, Offerhaus G, Pals S . CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value. Adv Cancer Res. 1999; 77:169-87. DOI: 10.1016/s0065-230x(08)60787-3. View

15.

Slomiany M, Dai L, Bomar P, Knackstedt T, Kranc D, Tolliver L . Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res. 2009; 69(12):4992-8. PMC: 3655760. DOI: 10.1158/0008-5472.CAN-09-0143. View

16.

Tran T, Kallakury B, Sheehan C, Ross J . Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol. 1997; 28(7):809-14. DOI: 10.1016/s0046-8177(97)90154-4. View

17.

Baumgartner G, Sakr L, Ulsperger E, Wogritsch C . The impact of extracellular matrix on the chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett. 1998; 131(1):85-99. View

18.

Martin T, Harrison G, Mansel R, Jiang W . The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol. 2003; 46(2):165-86. DOI: 10.1016/s1040-8428(02)00172-5. View

19.

Colnot D, Roos J, de Bree R, Wilhelm A, Kummer J, Hanft G . Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2003; 52(9):576-82. PMC: 11032944. DOI: 10.1007/s00262-003-0396-5. View

20.

Laurent T, Laurent U, Fraser J . The structure and function of hyaluronan: An overview. Immunol Cell Biol. 1996; 74(2):A1-7. DOI: 10.1038/icb.1996.32. View